ALDA Pharmaceuticals Corp.

ALDA Pharmaceuticals Corp.

March 04, 2008 13:28 ET

ALDA Receives US Patent No. 7,338,927 for T36®

VANCOUVER, BRITISH COLUMBIA--(Marketwire - March 4, 2008) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH) ("ALDA") is pleased to announce that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent Number 7,338,927 today. The patent provides protection for the composition and production methods for ALDA's T36® formulation until August 20, 2022. The patent can be viewed on the website of the USPTO.

Dr. Terrance Owen, President & CEO, states, "Issuance of the US patent is an important achievement for ALDA. Although we had previously been advised that the patent was supposed to be issued today, it is never certain until it is actually issued. Obviously, the United States is a very large market for ALDA's products and the Company can now move forward with confidence that this component of its intellectual property protection is in place. This is an important asset to have in place and we are very pleased to have this important confirmation that this component of ALDA's technology is novel and inventive."

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

Terrance G. Owen, Ph.D., MBA, President, CEO and Director

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.

Contact Information

  • ALDA Pharmaceuticals Corp.
    Terrance G. Owen, Ph.D., MBA
    President, CEO and Director
    (604) 521-8300
    ALDA Pharmaceuticals Corp. - Distribution & Sales Contact
    Peter Chen
    CFO and Director
    (604) 521-8300 Ext. 3
    (604) 521-8322 (FAX)
    ALDA Pharmaceuticals Corp. - Investor Relations Contact
    Scott Young
    (604) 288-7222